An open clinical trial of a new mouth-PUVA variant in the treatment of oral lichenoid lesions.
OBJECTIVE
To investigate the feasibility of topical psoralen PUVA (sensitization in photosensitizing psoralen drug + UVA radiation) treatment of oral lichenoid lesions (OLL).


METHODS
A total of 16 patients with OLL were treated using a 0.01% trioxsalen ointment and UVA doses in the 0.09 to 1.80 J/cm2 range. The average number of sessions was 8.7 and a mean cumulative irradiation dose was 4.25 J/cm2.


RESULTS
A marked-to-complete healing occurred in 3 to 16 (19%) patients immediately after therapy, in 4 of 14 (29%) after 3 months, and in 5 of 14 (38%) after 14 months, respectively. Of the 16 subjects with OLL, five were diagnosed as oral lichen planus (OLP) and 11 were classified as oral lichenoid reaction (OLR). Post-PUVA amelioration rate in patients with genuine OLP (4 of 5, 80%) was superior to that in patients with OLR (1 of 9, 11%).


CONCLUSIONS
Topical trioxsalen photosensitization can be used in mouth-PUVA treatment, and lichen planus is a main indication for this therapy.
Kuusilehto
A
A
Institute of Dentistry, University of Turku, Finland.
Lehtinen
R
R
Happonen
R P
RP
Heikinheimo
K
K
Lehtimäki
K
K
Jansén
C T
CT
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017676:Lichen Planus, Oral / Q000188:drug therapy*; D017512:Lichenoid Eruptions / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy; D009824:Ointments; D011701:PUVA Therapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use; D011829:Radiation Dosage; D012074:Remission Induction; D016896:Treatment Outcome; D014307:Trioxsalen / Q000008:administration & dosage / Q000627:therapeutic use
D009824:Ointments; D017319:Photosensitizing Agents; D014307:Trioxsalen